CTIL-052A is under clinical development by Cellular Biomedicine Group and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTIL-052A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
C-TIL052A is under development for the treatment of recurrent and or metastatic cervical cancer. The drug candidate is an autologous tumor infiltrating lymphocytes (TIL) and administered through parenteral route.
For a complete picture of CTIL-052A’s drug-specific PTSR and LoA scores, buy the report here.